AM-Pharma is developing a treatment for acute kidney injury (AKI) that could be life saving.
AM-Pharma’s purpose is to save the lives of patients confronted with sepsis, kidney disease and organ injury. Our initial focus is sepsis-associated acute kidney injury, the cause of death for hundreds of thousands of people hospitalized each year. Our proprietary recombinant human alkaline phosphatase has the potential to become the first treatment for sepsis-associated acute kidney injury and is about to be evaluated in a global pivotal Phase III clinical trial. We are a dedicated team driven to bring treatment options to severely ill patients, their families and acute care professionals.